Data to be presented include analyses of long-term efficacy and safety of ozanimod in adults with relapsing forms of multiple sclerosis and effects on biomarkers of disease activit
source https://finance.yahoo.com/news/data-ozanimod-clinical-development-program-113000650.html?.tsrc=rss
blaineonline.finance.blog 